Tedizolid phosphate (Sivextro®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015001231
English
Authors' recommendations:
Tedizolid phosphate (Sivextro®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with acute bacterial and skin structure infections (ABSSSI) caused by Gram-positive Staphylococcus aureus (specifically methicillin-resistant [MRSA] isolates) as an alternative oxazolidinione antibacterial. Treatment should only be initiated on advice from local microbiologists or specialists in infectious diseases. Tedizolid phosphate (Sivextro®) is not recommended for use within NHS Wales outside of this subpopulation/circumstance.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1607
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Anti-Bacterial Agents
- Methicillin Resistance
- Methicillin-Resistant Staphylococcus aureus
- Skin Diseases, Bacterial
- Staphylococcal Infections
- Adult
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.